


**Product Name** : Lys05  
**Cat. No.** : PC-60601  
**CAS No.** : 1391426-24-6  
**Molecular Formula** : C<sub>23</sub>H<sub>26</sub>Cl<sub>5</sub>N<sub>5</sub>  
**Molecular Weight** : 549.75  
**Target** : Autophagy  
**Solubility** : 10 mM in DMSO



## Biological Activity

Lys05 (Lys01 trihydrochloride, PS-1001) is the water-soluble salt of Lys01, is a 10-fold more potent **lysosomal autophagy** inhibitor than hydroxychloroquine (HCQ), also is a **Kir4.1** inhibitor.

Lys05 shows IC<sub>50</sub> values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay

Lys05 is more potently accumulates within and deacidifies the lysosome, resulting in impaired autophagy and tumor growth.

Lys05 enhances sunitinib-mediated suppression of clear cell ovarian carcinoma (CCOC) cell viability.

Lys05 is a potent, selective inhibitor of astrocytic inwardly rectifying potassium channel 4.1 (**Kir4.1**), inhibits inward and outward potassium currents with IC<sub>50</sub> of 0.22 and 0.18 μM, respectively.

Lys05 preferentially inhibits the Kir4.1 channel over other Kir isoforms, displays selectivity against other classes of potassium channels, such as astrocyte-expressing TWIK1, THIK1, TREK1 and neuronal KCNQ2, KCNQ3 channels, as well as cardiac hERG channels.

A single dose of Lys05 reversed the Kir4.1-driven depression-like phenotype and exerted rapid-onset antidepressant actions in multiple canonical depression rodent models with efficacy comparable to that of (S)-ketamine.

## References

McAfee Q, et al. *Proc Natl Acad Sci U S A*. 2012 May 22;109(21):8253-8.

Amaravadi RK, et al. *Autophagy*. 2012 Sep;8(9):1383-4.

DeVorkin L, et al. *Mol Cancer Res*. 2017 Mar;15(3):250-258.

Ndoye A, et al. *Cancer Res*. 2017 Nov 1;77(21):5873-5885.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com